A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration

A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration

Abstract Background Maladaptive immune responses during cerebral malaria (CM) result in high mortality despite opportune anti-malarial chemotherapy. Rapamycin, an FDA-approved immunomodulator, protects against experimental cerebral malaria (ECM) in mice through effects on the host. However, the pote...

Full description

Bibliographic Details
Main Authors: Pedro Mejia, J. Humberto Treviño-Villarreal, Justin S. Reynolds, Mariana De Niz, Andrew Thompson, Matthias Marti, James R. Mitchell
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Malaria Journal
Subjects:
Cerebral malaria
Rapamycin
Parasite sequestration
Endothelial activation
Online Access:http://link.springer.com/article/10.1186/s12936-017-2092-5

Internet

http://link.springer.com/article/10.1186/s12936-017-2092-5

Similar Items